At CPHI Frankfurt, we sat down with Peter Bains, MD & CEO of Syngene International, to discuss the company’s recent investments in peptides and antibody–drug conjugates (ADCs) and the broader evolution of integrated development in biologics.
At CPHI Frankfurt, we sat down with Peter Bains, MD & CEO of Syngene International, to discuss the company’s recent investments in peptides and antibody–drug conjugates (ADCs) and the broader evolution of integrated development in biologics.
Shutterstock - DIA TV
The week's biggest stories from this industry, direct to your inbox.
